Clinical Trials
15 trialsNCT06035497 2026-05-01
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Phase 1/2 Active not recruiting
NCT05463263 2026-04-23
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Step Pharma, SAS
Phase 1/2 Recruiting
NCT07496229 2026-04-17
Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
Dizal Pharmaceuticals
Phase 1/2 Recruiting
NCT06492304 2026-04-03
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies
CRISPR Therapeutics
Phase 1/2 Completed
NCT03590574 2026-03-16
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Autolus Limited
Phase 1/2 Terminated
NCT04752826 2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2 Recruiting
NCT06761677 2026-02-05
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
Phase 1/2 Suspended
NCT04104776 2025-05-15
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
Phase 1/2 Recruiting
NCT00888927 2024-04-25
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
Kyowa Kirin Co., Ltd.
Phase 1/2 Completed
NCT05138458 2023-11-13
IMAGINE
Myeloid Therapeutics
Phase 1/2 Suspended
NCT03770000 2022-10-28
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
Rhizen Pharmaceuticals SA
Phase 1/2 Completed
NCT01994382 2022-04-05
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Alexion Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00481871 2020-01-07
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Acrotech Biopharma Inc.
Phase 1/2 Completed
NCT02742727 2016-12-06
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 1/2 Unknown
NCT00742495 2012-10-24
BCX1777-108
Mundipharma Research Limited
Phase 1/2 Terminated